We’re briefing on the Hill. This coming Tuesday, APC is holding a pharmacy compounding policy...
APC in Inside Health Policy. APC’s demand that FDA reverse course on its ban of DTE in compounding has made it mainstream — Inside Health Policy not only covered our letter to the agency, it did so in one of the best, most comprehensive and accurate stories we’ve seen on the issue. Check out, “Amid CDER Chaos, Compounders Want Reversal Of Tidmarsh’s DTE Move”.
So good, so good, so good. Our New England regional meeting was a cozy affair befitting the location and the season. Attendees had a great evening with cocktails, dinner, networking, a policy update, and more. A big thanks to Colanar for sponsoring it!
Maybe experts don’t need committees? FDA commish Marty Makary took a shot at the agency’s advisory committees, calling them “bureaucratic, long and often conflicted, and very expensive.” He was talking specifically about why the FDA didn’t convene a panel of outside advisers before recommending the removal of the boxed warning on hormone replacement therapy, but it could signal another shift in how the agency uses its experts to make policy decisions. Editorially: It has to be better than the current stacked-deck PCAC process.
Reminder: If you want to serve the profession…. If you’re interested in serving on a 2026 APC committee — helping shape the future of pharmacy compounding — time is running out to submit your interest form. In fact, you only have a few weeks — till Thursday, Nov. 21. So if you have ideas you want to share — and develop! — to enhance the future of compounding, don’t wait. Click here and fill out and submit the interest form. And if you have questions, reach out to APC staff at info@a4pc.org.
